Quarter 1 2026-27:
Results and Forecast Report

13 August 2026

Quarter 1 performance at a glance

National medicine licence applications delivered on time

Vaccines and blood products certified on time



Customer satisfaction with scientific advice (30 day target)

Median time to provide written scientific advice (30 day target)

New manufacturing licences (90 day target)

Median vaccine batch testing time (43 day target)

Customer enquiries handled



FOI requests responded to on time

Confidence in performance

Clinical trials and investigations assessed on time

Recognition of international medicines licences determined on time

Adverse incidents processed within 24 hours

Vaccines and blood products certified on time



National variations determined on time

Scientific advice requests written advice delivered on time

National medicines licence applications determined on time

Decisions on manufacturing and distribution authorisations made on time

End of the year 2025–26

Q1 2025 26

Timely decisions on clinical trials and investigations

		Median time target (days)	Median time Q1 (days)	Minimum time Q1 (days)	Maximum time Q1 (days)
Clinical trial authorisations	Initials	30	29	1	70
	Modifications	35	35	1	52
Clinical investigations	Initials	60	58	52	60
	Modifications	21	6	0	38

Quality scientific advice

Scientific advice	Median time target (days)	Median time Q1 (days)	Minimum time Q1 (days)	Maximum time Q1 (days)
Time to offer a meeting	10	4	0	13
Time to offer written advice	30	24	0	34
End to end timeline across regulatory services	N/A	67	35	143

Quality of advice service score:



Overall experience with MHRA:



Reliable licensing timelines

		Median time target (days)	Median time Q1 (days)	Minimum time Q1 (days)	Maximum time Q1 (days)
National marketing authorisations granted	Established medicines	210	196	50	210
	New active substances	210	162	157	167
IRP marketing authorisations granted	Route A	60	57	47	60
	Route B	110	104	38	111

Robust variations timelines

Measure	Median time target (days)	Median time Q1 (days)	Minimum time Q1 (days)	Maximum time Q1 (days)
Type Ib – National	30	15	0	119
Type Ib – Safety	30	15	0	35
Type II – National	90	56	0	122
Type II – Safety	90	56	0	248

Consistent timelines for wholesale dealer and manufacturing licences

		Median time target (days)	Median time Q1 (days)
Wholesale Dealer Licences	New application	90	50
	Variation: Inspection	90	38
	Variation: No inspection	30	15
Manufacturing Licences	New application	90	34
	Variation: Inspection	90	43
	Variation: No inspection	30	13

Responsive batch control testing delivery

		Median time target (days)	Median time Q1 (days)	Minimum time Q1 (days)	Maximum time Q1 (days)
Batch Control Testing	Blood products	15	5	0	22
	Vaccines	43	3	0	30

Transparent and timely responses

Category	Parliamentary questions	Customer enquiries	Complaints	FOI requests
Volume	92	11,323	5	278
Q1 Responded on time	95%	93%	100%	97%
Target for on-time responses	85%	90%	90%	90%

Forecast for next quarter

Publish MHRA2030 Strategy

Welcome recommendations of the National Commission into the Regulation of AI in Healthcare

Consult on future of MHRA fees

Advance innovative access and licensing pathways

Showcase priorities at the MHRA-DIA Global Annual Summit

Thank you